Composicion farmacéutica de administracion oral que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos betabloqueantes para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 2: Composicion farmacéutica segun la reivindicacion 1 donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 4: Composicion farmacéutica segun la reivindicacion 1 donde el radical alqui...

La presente invencion se refiere al uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas por ejemplo de un los hemangiomas infantiles. El beta bloqueante puede ser un beta bloqueante no selectivo por ejemplo propranolol. La presente invencion proporciona una alternativa a los compuestos conocidos por ej. corticoides interferon o vincristina que se usan generalmente para el tratamiento de los hemangiomas. Reivindicacion 4: El uso de acuerdo con la...

Sustained release compositions of sotalol or a pharmaceutically acceptable salt thereof are provided. In certain examples sotalol or a pharmaceutically acceptable salt thereof may be administered in an effective amount to provide a therapeutic effect to a patient such as for example a patient suffering from a cardiac disorder. In some examples sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period e.g. at least about 24...

Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at lea...

The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads where each population of beads includes a beta-blocker. The beads may be selected from immediate-release beads enteric-release beads sustained-release beads and time-sustained-release beads. The beta-blo...

Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at lea...

Sustained release compositions of sotalol or a pharmaceutically acceptable salt thereof are provided. In certain examples sotalol or a pharmaceutically acceptable salt thereof may be administered in an effective amount to provide a therapeutic effect to a patient such as for example a patient suffering from a cardiac disorder. In some examples sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period e.g. at least about 24...